Pharsight

Gilead Sciences patents expiration

1. Atripla patents expiration

ATRIPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months from now)

US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months from now)

US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months from now)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months from now)

US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form
Apr, 2029

(5 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage

ATRIPLA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic